BioStock meets industry experts at BIO-Europe

EBD Group event BIO-Europe After thirty years, the event continues to consolidate its position as one of the life science industry's most important meeting places. This year, over 30 meetings have been booked and, as in previous years, a wide range of workshops, presentations and panel discussions on the future of the industry and the latest research advances are also offered.

Investors are flocking to the congress floor

In the crowd, BioStock met Dr. Gene Cho, Managing Partner of the new US-based VC fund Valuence Ventures which primarily focuses on new tools and technologies, such as AI-driven innovation. So far this year, five investments have been made and two to three more may be relevant before the end of the year, followed by several more in 2025.

For BioStocks Natasha Bank Cho talks about the great investment opportunities the fund sees in the European region. When asked what can make an investment case stand out from the crowd, he highlights the value of being able to present a strong go-to-market strategy, even in the early stages of development. Watch the interview here.

We also met Ted Fjällman, CEO of Flerie Invest, who talks about the investment strategy of the listed investment company that currently boasts a portfolio of 29 companies. The fund specializes in long-term investments and sees itself more as a company builder than an investor. Watch the interview here.

Lydia Kalafateli, Venture Developer & Lead Biotech in Dutch NLC Health Ventures, talks about the fund's focus on very early-stage programs. It often enters early in the development phase and assists in both founding and financing new life science companies. With around a hundred companies in its portfolio, NLC is at BIO-Europe to seek both new investments and partnership opportunities for existing portfolio companies. Watch the interview here.

Interesting companies are attracting interest

At BIO-Europa, many life science companies also share. One such company is ExpreS2ion Biotechnologies who are exploring partnership opportunities while preparing for Phase I with their breast cancer vaccine candidate, ES2B-C001CEO Bent. U Frandsen tells BioStock that it is important to initiate discussions early, with the aim of building relationships with potential takers and being able to conclude an attractive agreement later on.

Another company representative present is Professor Carl Borrebaeck, Chairman of the Board of PainDrainer and a pioneer in precision medicine with many years of experience in biotechnology innovation. In our interview He shares PainDrainer's progress in AI-powered solutions that offer personalized help to patients with chronic pain. With both regulatory approval and subsidy status in the US, the future looks bright and Borrebeack maintains the company's future potential.